TITLE

Development of a simultaneous boost IMRT class solution for a hypofractionated prostate cancer protocol

AUTHOR(S)
Mott J H; Livsey J E; Logue J P
PUB. DATE
May 2004
SOURCE
British Journal of Radiology;May2004, Vol. 77 Issue 917, p377
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The purpose of this work was to develop a robust technique for planning intensity-modulated radiation therapy (IMRT) for prostate cancer patients who are to be entered into a proposed hypofractionated dose escalation study. In this study the dose escalation will be restricted to the prostate alone, which may be regarded as a concurrent boost volume within the overall planning target volume (PTV). The dose to the prostate itself is to be delivered in 3 Gy fractions, and for this phase of the study the total prostate dose will be 57 Gy in 19 fractions, with 50 Gy prescribed to the rest of the PTV. If acute toxicity results are acceptable, the next phase will escalate doses to 60 Gy in 20 x 3 Gy fractions. There will be 30 patients in each arm. This work describes the class solution which was developed to create IMRT plans for this study, and which enabled the same set of inverse planning parameters to be used during optimization for every patient with minimal planner intervention. The resulting dose distributions were compared with those that would be achieved from a 3D conformal radiotherapy (3DCRT) technique that used a multileaf collimator (MLC) but no intensity modulation to treat the PTV, followed by a sequential boost to raise the prostate to 57 Gy. The two methods were tested on anatomical data sets for a series of 10 patients who would have been eligible for this study, and the techniques were compared in terms of doses to the target volumes and the organs at risk. The IMRT method resulted in much greater sparing of the rectum and bladder than the 3DCRT technique, whilst still delivering acceptable doses to the target volumes. In particular, the volume of rectum receiving the minimum PTV dose of 47.5 Gy was reduced from a mean value of 36.9% (range 23.4% to 61.0%) to 18.6% (10.3% to 29.0%). In conclusion, it was found possible to use a class solution approach to produce IMRT dose escalated plans. This IMRT technique has since been implemented clinically for patients enrolled in the hypofractionated dose escalation study.
ACCESSION #
14593982

 

Related Articles

  • Does radical treatment have a role in the management of low-risk prostate cancer? The place for brachytherapy and external beam radiotherapy. Williams, Scott; Zietman, Anthony // World Journal of Urology;Oct2008, Vol. 26 Issue 5, p447 

    A number of forms of radiation therapy are now commonly used for the treatment of low-risk prostate cancer (LRPCa). The tumour control rates are typically excellent, and the risk of death from prostate cancer very low regardless of the treatment modality. This is despite there being a paucity of...

  • Lower Urinary Tract Symptoms Affect One-Third of Men in a Prostate Cancer Screening Population. Jochen Walz; Nazareno Suardi; Georg C. Hutterer; Paul Perrotte; Andrea Gallina; Francois Bnard; Luc Valiquette; Michael McCormack; Markus Graefen; Francesco Montorsi; Pierre I. Karakiewicz // Journal of Endourology;Feb2008, Vol. 22 Issue 2, p369 

    PurposeLower urinary tract symptoms (LUTS) are common in elderly men. Radical prostatectomy may relieve obstructive symptoms, whereas radiation therapy may exacerbate obstructive or irritative symptoms. Baseline LUTS rates are unknown in populations screened for prostate cancer (PCa). Thus, it...

  • Bildgestützte Strahlentherapie. Wenz, F.; Belka, C.; Reiser, M.; Schönberg, S.O. // Der Radiologe;Mar2012, Vol. 52 Issue 3, p207 

    Clinical issue: The introduction of image-guided radiotherapy (IGRT) has changed the workflow in radiation oncology more dramatically than any other innovation in the last decades. Standard treatment: Imaging for treatment planning before the initiation of the radiotherapy series does not take...

  • Radiation therapy dose escalation for prostate cancer: a rationale for IMRT. Pollack, Alan; Hanlon, Alex; Horwitz, Eric M.; Feigenberg, Steven; Uzzo, Robert G.; Price, Robert A. // World Journal of Urology;Sep2003, Vol. 21 Issue 4, p200 

    The response of prostate cancer to radiation was well-documented in the pre-PSA era. Large palpable tumors resolved within months of treatment with relatively modest radiation doses of 64–70 Gy. The use of PSA-based failure as an endpoint, however, has made it clear that cure rates were...

  • External beam radiation therapy: role of androgen deprivation. Kupelian, Patrick // World Journal of Urology;Sep2003, Vol. 21 Issue 4, p190 

    Investigates the role of androgen deprivation (AD) in combination with external beam radiation therapy (RT) in the management of locally advanced prostate cancers. Examination of the mechanism of the interaction between AD and RT; Assessment of hormonal therapy methods; Discussion of the...

  • Radiation for prostate cancer issue. Theodorescu, Dan; Pollack, Alan // World Journal of Urology;Sep2003, Vol. 21 Issue 4, p189 

    Focuses on the evolution of radiotherapy treatment for prostate cancer. Impact of the advances in brachytherapy, external beam radiotherapy, and the combination of both on biochemical and clinical results; Technological developments and patient outcomes; Emergence of biomarkers for selection of...

  • Interactive digital slides with heat maps: a novel method to improve the reproducibility of Gleason grading. Egevad, Lars; Algaba, Ferran; Berney, Daniel; Boccon-Gibod, Liliane; Compérat, Eva; Evans, Andrew; Grobholz, Rainer; Kristiansen, Glen; Langner, Cord; Lockwood, Gina; Lopez-Beltran, Antonio; Montironi, Rodolfo; Oliveira, Pedro; Schwenkglenks, Matthias; Vainer, Ben; Varma, Murali; Verger, Vincent; Camparo, Philippe; Berney, Daniel M; Compérat, Eva // Virchows Archiv;Aug2011, Vol. 459 Issue 2, p175 

    Our aims were to analyze reporting of Gleason pattern (GP) 3 and 4 prostate cancer with the ISUP 2005 Gleason grading and to collect consensus cases for standardization. We scanned 25 prostate biopsy cores diagnosed as Gleason score (GS) 6-7. Fifteen genitourinary pathologists graded the digital...

  • Epcam, CD44, and CD49f Distinguish Sphere-Forming Human Prostate Basal Cells from a Subpopulation with Predominant Tubule Initiation Capability. Changyong Guo; Haibo Liu; Bao-Hui Zhang; Cadaneanu, Radu M.; Mayle, Aqila M.; Garraway, Isla P. // PLoS ONE;Apr2012, Vol. 7 Issue 4, p1 

    Background: Human prostate basal cells expressing alpha-6 integrin (CD49fHi) and/or CD44 form prostaspheres in vitro. This functional trait is often correlated with stem/progenitor (S/P) activity, including the ability to self-renew and induce differentiated tubules in vivo. Antigenic profiles...

  • Viral Integration Sites for New Prostate Cancer Virus. Klein, Eric; Silverman, Robert // AUANews;Aug2007, Vol. 12 Issue 8, p1 

    The article reports on the viral integration sites for new prostate cancer virus. The author said that for retroviruses that contain an oncogene in the viral DNA, integration allows for oncogene expression and results in tumor development. Recently, a research has identified the chromosomal...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics